AlphaQuest LLC Has $321,000 Stock Holdings in Denali Therapeutics Inc. $DNLI

AlphaQuest LLC lessened its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 8.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,964 shares of the company’s stock after selling 2,096 shares during the quarter. AlphaQuest LLC’s holdings in Denali Therapeutics were worth $321,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Caitong International Asset Management Co. Ltd increased its position in shares of Denali Therapeutics by 277.0% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock worth $29,000 after purchasing an additional 1,551 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Denali Therapeutics during the 1st quarter worth approximately $41,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Denali Therapeutics by 15.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after purchasing an additional 753 shares during the last quarter. Entropy Technologies LP acquired a new position in shares of Denali Therapeutics during the 1st quarter worth approximately $152,000. Finally, E Fund Management Co. Ltd. increased its position in shares of Denali Therapeutics by 20.7% during the 1st quarter. E Fund Management Co. Ltd. now owns 12,069 shares of the company’s stock worth $164,000 after purchasing an additional 2,072 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Stock Up 0.8%

DNLI stock opened at $16.38 on Friday. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $2.39 billion, a PE ratio of -5.85 and a beta of 1.30. Denali Therapeutics Inc. has a 1-year low of $10.57 and a 1-year high of $33.33. The business’s 50 day simple moving average is $15.12 and its 200 day simple moving average is $14.59.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.02. During the same period last year, the business earned ($0.59) EPS. As a group, research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Insiders Place Their Bets

In other Denali Therapeutics news, insider Carole Ho sold 2,937 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider directly owned 217,391 shares of the company’s stock, valued at $2,952,169.78. This represents a 1.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Alexander O. Schuth sold 2,937 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the transaction, the insider directly owned 242,346 shares in the company, valued at approximately $3,291,058.68. This represents a 1.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 6,680 shares of company stock worth $91,569. Insiders own 12.50% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Denali Therapeutics in a research report on Monday, September 8th. TD Cowen raised Denali Therapeutics to a “strong-buy” rating in a research report on Monday, July 28th. Finally, Morgan Stanley lowered their price target on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, August 18th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Denali Therapeutics has an average rating of “Buy” and a consensus target price of $33.50.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.